<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793360</url>
  </required_header>
  <id_info>
    <org_study_id>SN-C-00015</org_study_id>
    <nct_id>NCT04793360</nct_id>
  </id_info>
  <brief_title>Molecular Assessment and Profiling of Liver Transplant Recipients</brief_title>
  <acronym>MAPLE</acronym>
  <official_title>Molecular Assessment and Profiling of Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to conduct longitudinal and prospective studies of liver&#xD;
      transplant recipients, using a multimodality approach, akin to that used in kidney&#xD;
      transplantation. The primary aim will compare the clinical outcomes of LiverCare&#xD;
      post-transplant surveillance in liver transplant with standard of care consisting of liver&#xD;
      function tests, DSA measurements, drug level monitoring, and 'for cause' biopsy. The protocol&#xD;
      will assess the correlation between clinical events (e.g. rejection, recurrent disease,&#xD;
      biliary obstruction), dd-cfDNA levels, gene expression profiling, ability to assess&#xD;
      microchimerism, develop predictive analytics, infectious disease diagnoses and finally&#xD;
      examine graft histology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate the results of LiverCare with clinically significant events impacting post-transplant clinical outcomes, histological findings, and the development of de novo Donor Specific Antibody (DSA)</measure>
    <time_frame>2 years of accrual and 3 years follow up</time_frame>
    <description>LiverCare will be measured 7 times in year 1 and quarterly each year. A total of 15 surveillance points per subject in addition to for-cause testing based on clinical changes. Liver care will be collected at the time of all histologic analyses whether 'for cause' or 'surveillance'</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>LiverCare Surveillance</arm_group_label>
    <description>Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LiverCare</intervention_name>
    <description>The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.</description>
    <arm_group_label>LiverCare Surveillance</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All liver transplant patients without exclusion criteria will be eligible to enter the&#xD;
        study. Patients will be approached by the study team at the time of transplant or within 60&#xD;
        days post-transplant to discuss the trial, consent and enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver transplant recipients &lt;60 days post-transplant (de-novo or re-transplant).&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             trial.&#xD;
&#xD;
          -  Male or Female, aged 12 years or above (Gillick Competent).&#xD;
&#xD;
          -  In the Investigator's opinion, is able and willing to comply with all trial&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participant who is pregnant, lactating or planning pregnancy during the course&#xD;
             of the trial.&#xD;
&#xD;
          -  Has evidence of significant post-transplant impairment of hepatic function which is&#xD;
             unlikely to improve (determined by the PI).&#xD;
&#xD;
          -  Scheduled elective surgery or other procedures requiring general anaesthesia during&#xD;
             the trial.&#xD;
&#xD;
          -  Participant with life expectancy of less than 6 months or is inappropriate for&#xD;
             diagnostic monitoring through regular blood sampling.&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial.&#xD;
&#xD;
          -  Participants who have participated in another research trial involving an&#xD;
             investigational product in the past 12 weeks*.&#xD;
&#xD;
          -  Multi-organ transplant recipients or dual organ transplant recipients.&#xD;
&#xD;
          -  Patients with significant needle phobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jake Miles, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>CareDx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jake Miles, M.D.</last_name>
    <phone>(929) 363-5937</phone>
    <email>jmiles@caredx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Haydel</last_name>
      <email>Brandy.Haydel@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Sander Florman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonios Arvelakis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara Rocha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jawad Ahmad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charissa Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Crismale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priya Grewal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gene Im, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leona Kim-Schluger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Leong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Odin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamron Pourmand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schiano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

